Related Experiment Video
Updated: Jul 14, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Changing treatment protocol from azathioprine to mycophenolate mofetil: decrease in renal dysfunction, increase in
V Pourfarziani1, Y Panahi, S Assari
1Nephrology/Urology Research Center (NURC), Kidney Transplant Department, Baqiyatallah Medical Sciences University, Tehran, Iran. vahid.pourfarziani@gmail.com
Introduction:
Immunosuppression for renal transplantation has shifted from azathioprine (AZA) regimens to those containing mycophenolate mofetil (MMF). This study investigated the impact of this change on the causes for rehospitalization as well as on graft and patient survival.
Methods:
In this retrospective cohort study, we reviewed long-term patient and graft survivals as well as the causes of posttransplant admissions for 893 kidney recipients. Data on survival and readmissions were available for 811 subjects, who were divided to into the AZA cohort (n=289, transplantation between 1998 and 1999) and the MMF cohort (n=567, transplantation between 2000 and 2001). Survival, the cause for readmission, time interval between transplantation and readmission, intensive care unit (ICU) admission, mortality, and graft loss were compared between the two cohorts.
Results:
Five-year patient and graft survival rates were 85% and 67% for the AZA cohort and 91% and 68% for the MMF cohort (P=.013). There were 202 (71%) and 371 (72%) readmissions registered for the AZA and MMF groups, respectively. In comparison with the AZA cohort, while readmissions secondary to graft rejection showed a significant decrease in the MMF cohort (62% vs 35%, P=.000), readmissions secondary to infections exhibited a significant increase (37% vs 50%, P=.002). A marginally significant increased mortality rate (2% vs 5%, P=.087) and ICU admission rate (3% vs 6%, P=.062) were also observed in the MMF cohort by comparison with the AZA cohort.
Conclusion:
The shift in the immunosuppression protocol from AZA to MMF, albeit advantageous in many instances, can sometimes undermine the outcome by giving rise to such complications as high infection rates.
Insights
The shift from azathioprine (AZA) to mycophenolate mofetil (MMF) improved kidney transplant survival but increased infection-related hospitalizations. Careful monitoring is crucial for patients on MMF to manage these risks.
Area of Science:
- Nephrology
- Immunosuppression
- Transplantation Medicine
Background:
- Renal transplantation immunosuppression protocols have evolved from azathioprine (AZA) to mycophenolate mofetil (MMF).
- This transition aimed to improve patient and graft outcomes post-kidney transplant.
- Understanding the impact on rehospitalization causes is critical for optimizing care.
Purpose of the Study:
- To compare the impact of azathioprine (AZA) versus mycophenolate mofetil (MMF) immunosuppression on rehospitalization causes.
- To evaluate differences in patient and graft survival between AZA and MMF cohorts.
- To analyze post-transplant admission data, including reasons, timing, and critical care needs.
Main Methods:
- Retrospective cohort study of 893 kidney transplant recipients.
- Comparison of 289 patients on AZA (1998-1999) versus 567 patients on MMF (2000-2001).
- Analysis of long-term survival, rehospitalization rates, causes, ICU admissions, and mortality.
Main Results:
- Five-year patient survival improved from 85% (AZA) to 91% (MMF) (P=.013).
- MMF cohort showed significantly fewer rejections (35% vs 62%) but more infections (50% vs 37%) compared to AZA.
- Marginally increased mortality (5% vs 2%) and ICU admission (6% vs 3%) observed in the MMF group.
Conclusions:
- Mycophenolate mofetil (MMF) offers improved graft survival over azathioprine (AZA) in kidney transplantation.
- The shift to MMF is associated with a significant increase in infection-related rehospitalizations.
- While beneficial, MMF necessitates vigilant management to mitigate risks of infectious complications.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Cryptococcal Meningitis
Acute Kidney Injury IV: Diagnostic Studies and Prevention